therapeutically effective amounts of the compounds or compositions are administered.

In some embodiments, methods for selectively agonizing dopaminergic D_2 receptors (over other dopaminergic receptors) are provided. In other embodiments, methods of antagonizing or inhibiting (or not agonizing) activity of the 5-HT_2 receptors are also provided. In other embodiments methods and compounds for both selectively agonizing dopaminergic D_2 receptors and antagonizing (or not agonizing/very weak agonist activity) 5-HT_2 receptors at the same time are provided. Such methods and compounds may be desirable as agents for treating one or more symptoms of Parkinson's disease.

In one aspect, there is provided a use of a therapeutically effective amount of the compound as disclosed herein in the manufacture of a medicament for treating and/or preventing central nervous system disorders in a subject.

In one aspect, there is provided a use of a therapeutically effective amount of the compound as disclosed herein in the manufacture of a medicament for treating and/or preventing migraine in a subject.

In one aspect, there is provided a use of a therapeutically effective amount of the compound as disclosed herein in the manufacture of a medicament for treating and/or preventing Parkinson's disease in a subject.

In one aspect, there is provided a use of a therapeutically effective amount of the composition as disclosed herein in the manufacture of a medicament for treating and/or preventing Parkinson's disease in a subject.

DETAILED DESCRIPTION

Definitions

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art to which this invention belongs. In the event that there is a plurality of definitions for a term herein, those in this section prevail unless stated otherwise.

"Alkyl," by itself or as part of another substituent, refers to a saturated or unsaturated, branched, straight-chain or cyclic monovalent hydrocarbon radical derived by the removal of one hydrogen atom from a single carbon atom of a parent alkane, alkene or alkyne. Typical alkyl groups include, but are not limited to, methyl; ethyls such as ethanyl, ethenyl, ethynyl; propyls such as propan-1-yl, propan-2-yl, cyclopropan-1-yl, prop-1-en-1-yl, prop-1-en-2-yl, prop-2-en-1-yl (allyl), cycloprop-1-en-1-yl; cycloprop-2-en-1-yl, prop-1-yn-1-yl, prop-2-yn-1-yl, *etc.*; butyls such as butan-1-yl, butan-2-yl, 2-methyl-propan-1-yl, 2-methyl-propan-2-yl, cyclobutan-1-yl, but-1-en-1-yl, but-1-en-2-yl, 2-methyl-prop-1-en-1-yl, but-2-en-1-yl, but-2-en-2-yl, buta-1,3-dien-1-yl, buta-1,3-dien-2-yl, cyclobut-1-en-1-yl, cyclobut-1-en-3-yl, cyclobuta-1,3-dien-1-yl, but-1-yn-1-yl, but-1-yn-3-yl, but-3-yn-1-yl, *etc.*; and the like. The term "alkyl" is specifically intended to include groups having any degree or level of saturation, *i.e.*, groups having exclusively single carbon-carbon

25. The compound of Claim 21, wherein R_1 is $-CH_3$ or $-CF_3$, R_5 is methyl or allyl, and R_{11} is $-CF_3$.

26. A composition comprising the compound of Claim 1 and a vehicle.

27. ~~A method of treating and/or preventing central nervous system disorders in a subject comprising administering to the subject in need thereof~~ Use of a therapeutically effective amount of the compound of Claim 1 in the manufacture of a medicament for treating and/or preventing central nervous system disorders in a subject.

28. ~~A method of treating and/or preventing migraine in a subject comprising administering to the subject in need thereof~~ Use of a therapeutically effective amount of the compound of Claim 1 in the manufacture of a medicament for treating and/or preventing migraine in a subject.

29. ~~A method of treating and/or preventing Parkinson's disease in a subject comprising administering to the subject in need thereof~~ Use of a therapeutically effective amount of the compound of Claim 1 in the manufacture of a medicament for treating and/or preventing Parkinson's disease in a subject.

30. ~~A method of treating and/or preventing Parkinson's disease in a subject comprising administering to the subject in need thereof~~ Use of a therapeutically effective amount of the composition of Claim 1 in the manufacture of a medicament for treating and/or preventing Parkinson's disease in a subject.